The combination of 13N-ammonia and 11C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy

Zhang, Fangling; He, Qiao; Luo, Ganhua; Long, Ya‐Qiu; Li, Ruocheng; Ding, Lei; Zhang, Xiangsong

doi:10.1186/s12885-021-08574-1

Cited by 4 publications

(2 citation statements)

References 26 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 C-methionine PET (Met-PET) has been established to be beneficial in localizing the entire range of pituitary adenoma subtypes in terms of recurrent and newly diagnosed tumors [53,55,[57][58][59], especially microadenomas [7,55,60]. 11 C-methionine PET makes the most from a substantially lower brain uptake.…”

Section: C-methionine Petmentioning

confidence: 99%

New Progress in Imaging of Pituitary Diseases

Wu¹

2024

Frontiers in Neuroimaging

View full text Add to dashboard Cite

In the last 20 years, there have been advances in imaging techniques for pituitary diseases. Magnetic resonance imaging (MRI) particularly presents high-quality structural images and the essential information needed to authorize surgery, radiation therapy, and/or drug therapy. These images can assist in monitoring long-term outcomes. Recent technological advances, such as the advent of 7-Tesla MRI, have been used for measuring tumor consistency in pituitary adenomas. Microadenomas and other pituitary incidentaloma have been more recognized in the presence of golden-angle radial sparse parallel imaging and conventional dynamic contrast-enhanced techniques. However, standard structural (anatomical) imaging, mainly in the form of MRI, acts inadequately to identify all tumors, especially microadenomas (< 1 cm diameter), recurrent adenomas, and several incidentalomas. In this respect, nuclear isotope (radionuclide) imaging promotes tumor detection beneficially. All these imaging improvements may play a central role in clinical practice, especially when considering diagnosis, differential diagnosis, or definitive intervention. They further form accurate diagnosis, advise surgery, and decrease the risk of disrupting normal pituitary function.

show abstract

Section: C-methionine Petmentioning

confidence: 99%

New Progress in Imaging of Pituitary Diseases

Wu¹

2024

Frontiers in Neuroimaging

View full text Add to dashboard Cite

show abstract

“…Furthermore, [ 11 C]C-MET PET may incorrectly detect PAs. In addition, [ 13 N]N-ammonia ([ 13 N]N-NH3) was found to represent the metabolic integrity of pituitary tissue well [ 9 , 10 ]. In a previous study, we found that [ 13 N]N-NH3 demonstrated a higher uptake in pituitary tissue than in PAs, acting as a good tracer for normal pituitary tissue in patients with PAs [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Clinical application of combination [11C]C-methionine and [13N]N-ammonia PET/CT in recurrent functional pituitary adenomas with negative MRI or [18F]F-FDG PET/CT

Wang,

Feng,

Zhu

et al. 2024

BMC Endocr Disord

View full text Add to dashboard Cite

Background We assessed the value of positron emission tomography/computed tomography (PET/CT) with [13N]N-ammonia ([13N]N-NH3) and [11C]C-methionine ([11C]C-MET) for the evaluation and management of recurrent secreting pituitary adenoma, which could not be detected by magnetic resonance imaging (MRI) or fluorine-18 fluorodeoxyglucose ([18F]F-FDG) PET. Methods Nine consecutive patients with biochemical and clinical evidence of active recurrent tumor not detected by MRI and [18F]F-FDG PET were enrolled in this study. All of the patients underwent [13N]N-NH3 and [11C]C-MET PET/CT, after which the pattern of tracer uptake was studied, the tumor position was located, and a clinical decision was made. Results In general, [11C]C-MET had a higher uptake in pituitary adenomas (PAs) than that in pituitary tissues, while [13N]N-NH3 had a higher uptake in pituitary tissue than in pituitary adenomas. Increased [11C]C-MET uptake was observed in all nine PAs and three pituitary tissues, while all pituitary tissues and only one pituitary adenoma showed increased [13N]N-NH3 uptake. Four patients had concordant imaging and surgical findings indicative of biochemical remission without hypopituitarism after treatment. Radiotherapy was adopted in two patients, medication in another two, and follow-up observation in one case. Conclusion Combined [11C]C-MET and [13N]N-NH3 PET/CT is effective in the differentiation of PAs from pituitary tissue in recurrent functional PAs with negative MRI or [18F]F-FDG PET. These results provide a valuable reference for further disease management.

show abstract